Immunic (IMUX) Asset Writedowns and Impairment (2018)

Immunic's (IMUX) quarterly Asset Writedowns and Impairment came in at $1.2 million in Q3 2018.

Immunic (IMUX) Asset Writedowns and Impairment (2018) Analysis & Trends

Immunic has disclosed Asset Writedowns and Impairment across 1 years of filings, most recently posting $1.2 million for Q3 2018.

Asset Writedowns and Impairment for Q3 2018 came in at $1.2 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $1.2 million (changed N/A YoY), and the FY2018 annual result was $1.2 million, changed N/A from the prior year.
Asset Writedowns and Impairment came in at $1.2 million for Q3 2018 at Immunic.
In the past five years, Asset Writedowns and Impairment ranged from a high of $1.2 million in Q3 2018 to a low of $1.2 million in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Immunic	431.25 Mn	244.62 Mn	-

Download Data

Date	Value
Sep 30, 2018	1.22 Mn
Sep 30, 2018	1.22 Mn